Home
overview
If you want to keep up to date with the recent developments and advances in transgenic research, the easiest way is to attend SMi’s Innovations in Transgenic Technologies conference. SMi’s event offers you the simple way to stay ahead of the game, by covering the latest hot topics underlying transgenic organisms and their use in drug discovery.

The economic, regulatory and legal issues within the industry will also be discussed, with particular reference to patenting and regulatory compliance for transgenic technologies. The meeting aims to bring together leaders in the fields of biotechnology, and pharmaceutical development to offer an insight into the application of transgenic technologies in medicine and to analyse the future of the industry.

Why you should attend this event?

As a senior industry executive, you will be aware of the importance and potential of this field. This conference offers you the opportunity to discover the potential and realities of transgenic technologies, to match your company’s resources to the needs of drug discovery.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Mark Moore

Dr Mark Moore, Chief Scientific Officer, Deltagen

9:10 INTRODUCTION

Dr Kader Thiam

Dr Kader Thiam, Senior Scientific Consultant & Head, Immunology Department, genOway

  • Advances in DNA manipulation techniques
  • Current uses of transgenics
    Improving animal models
  • Current DNA insertion techniques
    DNA microinjection
  • Retrovirus-mediated transgenesis
  • Embryonic stem (ES) cell-mediated gene transfer
    Novel methods of DNA insertion
  • Applying transgenics in drug development
  • 9:40 TRANSGENICS: OVERCOMING BARRIERS TO PHARMACEUTICAL RESEARCH

    Dr Anthony Purchio

    Dr Anthony Purchio, Vice President & Chief Science Officer, Xenogen

  • Case study: Real-time in vivo imaging - technology to monitor bioactivity
  • In vivo imaging: visualising the way forward
  • More data, better quality
  • Widening the bottlenecks in drug discovery
  • Applications: how, where and why?
  • Predicting the future in pharmaceutical research
  • 10:20 USING ARTIFICIAL CHROMOSOMES TO PRODUCE NOVEL PROTEIN THERAPEUTICS

    Dr Joseph Zendegui

    Dr Joseph Zendegui, Vice President, Business Development, Chromos Molecular Systems

  • What is ACes technology
  • The Chromos Soloution
  • Applying ACes for transgenic production
  • Outlook- development of protein-based products
  • 11:00 Morning Coffee

    11:20 USING GENE TARGETED ANIMAL MODELS

    Dr Jeffry Vaught

    Dr Jeffry Vaught, President, Research & Development, Cephalon

  • Overview
  • Target selection
  • Strategy for Drug Discovery/Target Validation
  • Signal Transduction Modulators
  • Protease inhibitors
  • Neurotrophic factors
  • 12:00 ACCELERATED BACKCROSSING / SPEED CONGENICS

    Dr Will Gergits

    Dr Will Gergits, Managing Partner, Therion International & Charles River Laboratories

  • Directed versus random backcrossing breeding strategies
  • Background strain characterization
  • Introducing MAX-BAX™ technology
  • Case studies and strategy impact
  • Adherence to the three R’s Reduce, Refine, Replace
  • 12:40 Networking Lunch

    13:40 NON-VIRAL METHODOLOGY

    Dr Brian Davis

    Dr Brian Davis, President & Chief Executive Officer, Gene-Cell

  • Viral vs non viral vectors
  • Advancing gene therapy and functional genomics: Gene-Cell technologies
  • Glass needle microinjection technology
  • Gene modification technology: gene repair vs. gene compensation
  • Applications to transgenic technology
  • 14:20 TRANSGENICS IN MONOCLONAL ANTIBODY PRODUCTION

    Dr Geoffrey Davis

    Dr Geoffrey Davis, Chief Scientific Officer, Abgenix

  • ‘Magic bullets’; what is the significance of antibodies as a class of therapeutic drugs?
  • Human antibodies from immunised XenoMice™
  • How therapeutic, fully human antibodies will increase the pharmaceutical pipeline
  • Application of antibodies to validation of genomics targets
  • Improving therapeutics:
    - Accelerating the path to the clinic
    - Improving the side effect profile
  • 15:00 HIGH AFFINITY FULLY HUMAN MONOCLONAL ANTIBODIES

    Dr Kazuma Tomizuka

    Dr Kazuma Tomizuka, Senior Research Scientist, Kirin Brewery

  • The development of the TransChromo™ technology
  • The development of the TC mouse to:
  • Carry human immunoglobulin genes producing fully human antibodies
  • Generate high affinity, fully human antibodies
  • Generate hybridoma clones for the majority of Ig subclasses
  • The continuing development of TC Mouse technology
  • 15:40 Afternoon Tea

    16:00 ANALYSIS OF GENE FUNCTION AND TARGET VALIDATION

    Dr Peter Bluford

    Dr Peter Bluford, Vice President, Business Development, Sangamo Biosciences

  • Zinc finger DNA binding proteins (ZFPs)
  • Targeted gene regulation with ZFP transcription factors
  • Conditional knockouts with ZFP technology
  • Proprietary advantage of ZFP-transgenic models
  • Dealing with joint ownership and other collaborative IPR issues
  • 16:30 USING LENTIVIRUS TRANSFER SYSTEMS

    Dr Chris Mundy

    Dr Chris Mundy, Head, Gene Discovery, Oxford BioMedica

  • Development of minimal lentiviral vectors
  • Smartomics: target discovery focused by gene transfer
  • Target validation using LentiVectors
  • Application to neurodegenerative and other diseases
  • Future directions
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    17:10 Drinks Reception for Delegates & Speakers

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Geoff Cook

    Geoff Cook, Business Development Manager, PPL Therapeutics

    9:10 GENE EXPRESSION IN SKELETAL MUSCLE

    Dr Dominic Wells

    Dr Dominic Wells, Reader in Transgenic Biology, Imperial College School of Medicine

  • A platform for local or systemic distribution of protein products
  • Functional assays following germ line and somatic gene transfer
  • Improvements in somatic gene transfer technology
  • Barriers to clinical application
  • Combining germ-line and somatic gene transfer to model gene therapy
  • Future prospects
  • 9:40 INNOVATIONS IN ONCOLOGY

    Marlise Potelle

    Marlise Potelle, Director, Commercial Development, Genzyme Transgenics

  • Recent developments utilising transgenics in cancer research
  • From the lab to the real world, the market opportunities for products
  • Overcoming the challenges of implementing cancer technology
  • What the future holds for cancer research using transgenics
  • Future commercialisation of this technology
  • 10:20 LINKING RESEARCH WITH THERAPY IN CARDIOVASCULAR DISEASE

    Dr Ian Graham

    Dr Ian Graham, Senior Research Fellow, Division of Biochemistry, Royal Holloway University of London

  • Recent developments in the cardiovascular market using transgenics
  • Advantages of using transgenics to develop a CV therapeutic
  • Transgenic animal models of atherosclerosis
  • Interpretation of drug intervention transgenic studies
  • Future developments
  • 11:00 Morning Coffee

    11:20 NEURODEGENERATIVE DISEASE MODELS

    Dr Thomas Rosahl

    Dr Thomas Rosahl, Research Fellow, Merck Sharp & Dohme

  • An overview of animal models in Alzheimer’s Disease (AD)
  • What is the impact of gene disruption and transgenic technology in neurodegenerative research
  • Amyloid precursor protein and presenilin knockouts
  • Transgenes linked to familial early onset AD
  • Development of new strains relevant to Alzheimer's Disease Conditional transgenics
  • 12:00 XENOTRANSPLANTATION: IS THERE A FUTURE?

    Dr Julia Greenstein

    Dr Julia Greenstein, President & Chief Executive Officer, Immerge Biotransplant

  • The issues and need for xenotransplantation
  • Recent developments utilizing transgenics and nuclear transfer in xenotransplantation
  • Overcoming the challenges of xenotransplantation technology
  • Fighting the ethical battle- strategies for success/ is there really a choice?
  • What the future holds for xenotransplantation / commercialisation of this technology
  • 12:40 Networking Lunch

    13:40 VIRUS TRANSMISSION

    Dr Daniel Galbraith

    Dr Daniel Galbraith, Associate Director, Virology, Q-One Biotech

  • Animal viruses and Zoonosis
  • Safety testing strategies and how they are evolving
  • Retroviruses both endogenous and exogenous
  • Coping with the new emerging virus danger
  • 14:20 OLD MACDONALD HAD A BIOTECH COMPANY

    Dr Frank Pieper

    Dr Frank Pieper, Vice President, Research & Technology, The Pharming Group

  • Taking your ‘pharm’ produce to market
  • Novel methods for obtaining therapeutics
  • Producing high output levels without endangering host
  • Embryo viability
  • Health, Safety and Pharmacovigilance
  • 15:00 INTEGRATING DISCOVERY AND PRODUCTION OF NATURAL SOURCE THERAPEUTIC BIOLOGICS

    Dr Tulin Morcol

    Dr Tulin Morcol, Senior Scientist, BioSante Pharmaceuticals

  • To Genie with love: a personal story with the pioneer pig
  • Transgenic animal productivity
  • US market for ‘made in transgenic bioreactor’ pharmaceuticals
  • Past and present down-stream transgenic milk processing: benefits and limitations
  • Novel process for removal of caseins from milk of transgenic animals
  • Strategies for scale-up: integrating BioSante process into the existing stream
    Market application and exploitation
  • 15:40 Afternoon Tea

    16:00 TRANSGENIC CHICKEN BASED PROTEIN PRODUCTION

    Anthony Cruz

    Anthony Cruz, Vice President, Corporate Development & Strategic Planning, Avigenics

  • Biologics production: opportunities for the transgenic chicken
  • Advantages and current limitations of protein production from eggs
  • Progress of avian transgenic technology
  • From egg to drug: processing egg proteins
  • Strategic challenges: regulatory acceptance and public perception
  • Golden eggs: future use for commercial production
  • 16:30 RECOMBINANT PROTEINS FROM TRANSGENIC PLANTS

    Dr Manfred Theisen

    Dr Manfred Theisen, Scientific Director & Chief Scientific Officer, Meristem Therapeutics

  • Opportunities for large-scale protein production in agricultural systems
  • Transforming plants to produce antibodies and vaccines
  • Seed-based vs tissue-based systems
  • Manufacturing issues: producing therapeutic proteins using plant technology
  • The emerging regulatory environment
  • The future use of plant systems
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.